MARKET

CVKD

CVKD

Cadrenal Therape
NASDAQ
5.36
+0.05
+0.98%
Opening 10:00 05/14 EDT
OPEN
5.43
PREV CLOSE
5.31
HIGH
5.45
LOW
5.06
VOLUME
12.13K
TURNOVER
--
52 WEEK HIGH
16.25
52 WEEK LOW
4.210
MARKET CAP
15.38M
P/E (TTM)
-0.9487
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CVKD last week (0504-0508)?
Weekly Report · 3d ago
Cadrenal Therapeutics reports Q1 results
Seeking Alpha · 05/07 14:40
Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate
Benzinga · 05/07 13:00
Cadrenal Q1 net loss narrows 35.1% to $2.5 million
PUBT · 05/07 12:34
*Cadrenal Therapeutics 1Q Loss/Shr $1.04 >CVKD
Dow Jones · 05/07 12:32
*Cadrenal Therapeutics 1Q Research and Development Expenses $771,508 >CVKD
Dow Jones · 05/07 12:32
CADRENAL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES PHASE 3 DEVELOPMENT UPDATE ON CAD-1005 FOLLOWING END-OF-PHASE 2 MEETING WITH FDA
Reuters · 05/07 12:30
Press Release: Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Dow Jones · 05/07 12:30
More
About CVKD
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics to overcome the limitations of anticoagulation therapy. It has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.

Webull offers Cadrenal Therapeutics Inc stock information, including NASDAQ: CVKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVKD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVKD stock methods without spending real money on the virtual paper trading platform.